The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Politburo Meeting Sets Tone for "15th Five-Year Plan" Start, Addressing "Involuted" Competition and Implementing "AI Plus" Initiative

On April 28, the Political Bureau of the CPC Central Committee (中共中央政治局) held a meeting to analyze the current economic situation. The meeting noted that China's economy saw a strong start in the first quarter (GDP grew 5.0% year-on-year), with major indicators exceeding expectations. As the first Politburo meeting focused on economic work following the start of the "15th Five-Year Plan" (十五五) cycle, it released policy signals characterized by a high sense of urgency.

Ask EqualOcean — China Intelligence, On Demand

Your direct line to what's really happening in China.

Unpacking China | Key Chinese Firms to Watch This Week （19/04/2026-25/04/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.